Matches in Nanopublications for { ?s ?p "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 10 of
10
with 100 items per page.
- NP326757.RAr1EwyBWNjAMlRENmVw2yNnNDzjC2iQ48k8Nm5TohFos130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326757.RAr1EwyBWNjAMlRENmVw2yNnNDzjC2iQ48k8Nm5TohFos130_provenance.
- NP803700.RASqEhzm7IWyXNpzjXbDQkfFL2ejEkzkKBswHDkvnVcmo130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP803700.RASqEhzm7IWyXNpzjXbDQkfFL2ejEkzkKBswHDkvnVcmo130_provenance.
- NP405236.RAF6MvRkju3THSzpvH8NoihIITcL_DE2nqTsWAhZ8x5WY130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP405236.RAF6MvRkju3THSzpvH8NoihIITcL_DE2nqTsWAhZ8x5WY130_provenance.
- NP377837.RABKphyE_MIu1VZa7iegxM1L21bJ6A7QtoI9r9jg_aeNc130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP377837.RABKphyE_MIu1VZa7iegxM1L21bJ6A7QtoI9r9jg_aeNc130_provenance.
- NP531838.RA7n9bmUAiZV4DrOPznX0YqUpzUSXfAZHA1N_090Vu0B0130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP531838.RA7n9bmUAiZV4DrOPznX0YqUpzUSXfAZHA1N_090Vu0B0130_provenance.
- assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1021383.RAzrGJw9NczRymjnx_Bz5OxIPvwuoyLbVUTpwN2Im7Dew130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1021383.RAzrGJw9NczRymjnx_Bz5OxIPvwuoyLbVUTpwN2Im7Dew130_provenance.
- NP377835.RAOMoCyz2ncMg2LZ5HR6KI0NIhlOC7Etj4OXqO4x8WHos130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP377835.RAOMoCyz2ncMg2LZ5HR6KI0NIhlOC7Etj4OXqO4x8WHos130_provenance.
- NP1021379.RApME6M4M69RvFXfHOGvgbUMliDVRkibADEQqCpASyAZo130_assertion description "[Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) has emerged as an attractive target for the immunotherapy of GBM as it is overexpressed in glioma and promotes its malignant phenotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1021379.RApME6M4M69RvFXfHOGvgbUMliDVRkibADEQqCpASyAZo130_provenance.